We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Mechanism Boosts Effects of Cancer Treatments

By Biotechdaily staff writers
Posted on 06 Dec 2004
Scientists have found a new mechanism of pathway activation known to be involved in many cancers. More...
In addition, they discovered that when this mechanism is blocked, cells may become more sensitive to chemotherapeutic agents and radiation, thereby making them easier to kill.

Researchers from Mount Sinai School of Medicine (New York, NY, USA) studied the Wnt pathway, which is known to be essential to regulation of cell differentiation. Once differentiated, cell proliferation is restricted. When triggered, the Wnt pathway instructs cells not to differentiate, allowing them to grow uncontrollably, which can then lead to tumor development.

The Mount Sinai investigators found that in some ovarian, breast, and colon cancer cells this pathway becomes activated by the triggering of a receptor on the surface of the cell. The cell can stimulate itself, remain in an undifferentiated condition, and continue to grow unchecked. Also, they found that the pathway can be inactivated at the cell surface by compounds that block the receptor. When inactivated, these cancer cells become more sensitive to agents that induce cell death.

Whereas it has been known that the Wnt pathway is involved in nearly all cases of colon cancer and in some ovarian and skin cancers, this research was the first to implicate this pathway in breast cancer and to identify this mechanism in human tumor cells. The study was published in the November 2004 issue of Cancer Cell.

"An increasing number of cancer therapeutic agents are being developed to block pathways activated by interactions at the cell surface. This research provides a novel target to interfere with a pathway that is implicated in many cancer types,” remarked Dr. Stuart Aaronson, professor and chairman of oncologic sciences at Mount Sinai School of Medicine.

Dr. Anna Bafico, assistant professor of oncologic sciences at Mount Sinai concluded, "Selectively interfering in this pathway in cancer cells with this mechanism may make them more sensitive to existing treatments.”


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: LIAISON Murex Anti-HDV Immunoassay is the first fully automated FDA-authorized immunoassay for HDV detection in the U.S. (Photo courtesy of Diasorin)

Fully Automated Immunoassay Test Detects HDV Co‑Infection and Super-Infection

Hepatitis delta, also known as hepatitis D, is caused by the hepatitis delta virus (HDV). It is a viral liver infection that can result in one of the most severe forms of viral hepatitis.... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Industry experts gather at WHX Labs Dubai to discuss how leadership must adapt as AI and automation transform the laboratory (Photo courtesy of Shutterstock)

WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories

WHX Labs in Dubai (formerly Medlab Middle East), held at Dubai World Trade Centre (DWTC) from 10–13 February, brings together international experts to discuss the factors redefining laboratory leadership,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.